These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 29764853)

  • 21. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
    Burris HA; Dowlati A; Moss RA; Infante JR; Jones SF; Spigel DR; Levinson KT; Lindquist D; Gainer SD; Dar MM; Suttle AB; Ball HA; Tan AR
    Mol Cancer Ther; 2012 Aug; 11(8):1820-8. PubMed ID: 22679111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
    Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
    Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.
    Jones SF; Infante JR; Thompson DS; Mohyuddin A; Bendell JC; Yardley DA; Burris HA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):471-5. PubMed ID: 22851205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
    Mikhail S; Lustberg MB; Ruppert AS; Mortazavi A; Monk P; Kleiber B; Villalona-Calero M; Bekaii-Saab T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1005-12. PubMed ID: 26416564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
    Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
    Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
    J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
    van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; de Bono JS; Schellens JHM
    Invest New Drugs; 2020 Aug; 38(4):1117-1128. PubMed ID: 31667659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
    Sen S; Kato S; Agarwal R; Piha-Paul S; Hess K; Karp D; Janku F; Fu S; Naing A; Pant S; Falchook G; Tang C; Wu X; Ye Y; Tsimberidou A; Subbiah V; Kurzrock R; Byers L; Westin S; Lim J; Bean S; Bass A; Nguyen L; Meric-Bernstam F; Hong D
    Br J Cancer; 2018 May; 118(11):1419-1424. PubMed ID: 29695765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer.
    Lammers PE; Lu B; Horn L; Shyr Y; Keedy V
    Oncologist; 2015 May; 20(5):491-2. PubMed ID: 25845992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
    Gaillard SL; Zahurak M; Sharma A; Durham JN; Reiss KA; Sartorius-Mergenthaler S; Downs M; Anders NM; Ahuja N; Rudek MA; Azad N
    Cancer; 2019 Aug; 125(16):2837-2845. PubMed ID: 31012962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
    Langer CJ; Hirsh V; Ko A; Renschler MF; Socinski MA
    Clin Lung Cancer; 2015 Mar; 16(2):112-20. PubMed ID: 25572008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
    Hyman DM; Snyder AE; Carvajal RD; Gerecitano JF; Voss MH; Ho AL; Konner J; Winkelmann JL; Stasi MA; Monson KR; Iasonos A; Spriggs DR; Bialer P; Lacouture ME; Teitcher JB; Katabi N; Fury MG
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):747-55. PubMed ID: 25672916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.
    Grilley-Olson JE; Keedy VL; Sandler A; Moore DT; Socinski MA; Stinchcombe TE
    Oncologist; 2015 Feb; 20(2):105-6. PubMed ID: 25616430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
    Yap TA; O'Carrigan B; Penney MS; Lim JS; Brown JS; de Miguel Luken MJ; Tunariu N; Perez-Lopez R; Rodrigues DN; Riisnaes R; Figueiredo I; Carreira S; Hare B; McDermott K; Khalique S; Williamson CT; Natrajan R; Pettitt SJ; Lord CJ; Banerji U; Pollard J; Lopez J; de Bono JS
    J Clin Oncol; 2020 Sep; 38(27):3195-3204. PubMed ID: 32568634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.